CClinicalTrials.gg
TerminatedNCT05826704Updated Aug 15, 2024

Exploring the Effects of Lactobacillus Paracasei PS23 on Workplace-related Stress Symptoms Among Office Workers

An interventional study of Probiotics in Stress, sponsored by Mackay Memorial Hospital. Terminated at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Mackay Memorial Hospital · Not applicable, Interventional, and Supportive care

Why this study was terminated
The company had to re-decorate

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2022, registered Apr 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

A total of 120 subjects are expected to be recruited over a 3-year period starting after IRB approval, divided into two groups of 60 subjects, receiving PS23 or placebo, and completing a 6-week trial period.

Read the detailed description

There is still a lack of research to explore the interaction between high-pressure workers and probiotics to improve the intestinal microbiota and further affect its relationship with sleep, inflammation, and anti-oxidation, and further studies are still needed to confirm the clinical effect. A total of 120 subjects are expected to be recruited over a 3-year period starting after IRB approval, divided into two groups of 60 subjects, receiving PS23 or placebo, and completing a 6-week trial period.

02

Conditions studied

  • Stress
03

In context

Lead sponsor

Mackay Memorial Hospital is the lead sponsor of 118 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Administrative staff of JARLLYTEC CO., LTD.
  2. Age 20-65 years old
  3. Those who feel that they are in a medium to high stress situation

Exclusion criteria

Exclusion Criteria:

  1. Have taken antibiotics within one month or are receiving antibiotic treatment
  2. Have taken probiotic products within two weeks (excluding yogurt, yogurt, Yakult and other related foods)
  3. have a history of cancer
  4. Those who are allergic to lactic acid bacteria products
  5. Those who are currently taking medication for acute illness, mental illness or sleep disorder
  6. Pregnant or breastfeeding
  7. The project host judges that it is not suitable to participate in the researcher
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    PS23

    2 capsule daily

    Dietary Supplement: Probiotics

  • Placebo comparator
    Placebo

    2 capsule daily

    Dietary Supplement: Probiotics

Interventions

  • Dietary supplementProbiotics

    Participants will be taking 2 capsule a day for 6 weeks

06

What researchers measure

Primary outcomes

  1. Perceived Stress Scale, PSS

    The PSS scores is a rating tool used to gauge the course of stress. The minimum total score possible is 0 and the maximum total score possible is 56. Higher values represent a worse outcome.

    Time frame: From Baseline to 6 Weeks Assessed

Secondary outcomes

  1. Insomnia Severity Index, ISI

    The ISI is a rating tool used to gauge of sleeping. Higher values represent a worse outcome. The minimum total score possible is 0 and the maximum total score possible is 28. Higher values represent a worse outcome.

    Time frame: From Baseline to 6 Weeks Assessed

  2. The State-Trait Anxiety Inventory, STAI

    The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). The minimum total score possible is 40 and the maximum total score possible is 160. Higher scores indicate greater anxiety.

    Time frame: From Baseline to 6 Weeks Assessed

  3. Patient Health Questionnaire, PHQ-9

    Measure for Major Depressive Disorder from questionnaire responses, clinically significant depression defined as a PHQ-9 score of equal to or greater than 10.

    Time frame: From Baseline to 6 Weeks Assessed

  4. The Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form-16, QLESQ-16

    The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 (QLESQ-16) is a valid, reliable self-report instrument for assessing quality of life. The minimum total score possible is 14 and the maximum total score possible is 70. The higher score the better satisfaction.

    Time frame: From Baseline to 6 Weeks Assessed

  5. VAS-GI

    Visual Analogue Scale for GI symptoms, VAS-GI (visual analogue scale, VAS 0-10) was designed to measure the response of symptoms and well-being in patients after taking probiotics.

    Time frame: From Baseline to 6 Weeks Assessed

  6. Brief Fatigue Inventory

    Brief Fatigue Inventory( BFI)is a nine item scale used to evaluate the intensity of fatigue and the interference of fatigue to normal activities. The classification of fatigue severity is: Mild fatigue (1-3), Moderate fatigue (4-6) and Severe fatigue (7-10).

    Time frame: From Baseline to 6 Weeks Assessed

  7. Patient Global Impression scales of Improvement rated by patient, PGI-C

    The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy.

    Time frame: From Baseline to 6 Weeks Assessed

  8. Saliva Cortisol

    Cortisol is a steroid hormone that is produced by the adrenal glands which sit on top of each kidney. When released into the bloodstream, cortisol can act on many different parts of the body and can help: body respond to stress or danger increase your body's metabolism of glucose control your blood pressure reduce inflammation. Cortisol is also needed for the fight or flight response which is a healthy, natural response to perceived threats. The amount of cortisol produced is highly regulated by your body to ensure the balance is correct.

    Time frame: From Baseline to 6 Weeks Assessed

  9. Saliva α-amylase

    Salivary alpha-amylase activity (sAA) is often considered to be surrogate markers of sympathetic activation in response to stress.

    Time frame: From Baseline to 6 Weeks Assessed

  10. Saliva IgA

    Secretory IgA in saliva stands in a negative correlation to the level of the experienced stress

    Time frame: From Baseline to 6 Weeks Assessed

  11. Saliva Lactoferrin

    lactoferrin's multiple activities lie in its capacity to bind iron and to interact with the molecular and cellular components of hosts and pathogens. it can bind and sequester lipopolysaccharides, thus preventing pro-inflammatory pathway activation, sepsis and tissue damages.

    Time frame: From Baseline to 6 Weeks Assessed

  12. Saliva Lysozyme

    Lysozyme plays a pivotal role in the prevention of bacterial infections by attacking peptidoglycan in the bacterial cell wall.

    Time frame: From Baseline to 6 Weeks Assessed

  13. Job Stress Scale from the Ministry of Labor

    The job stress scale from Ministry of Labor is a rating tool used to gauge of stress.

    Time frame: From Baseline to 6 Weeks Assessed

07

Study locations

1 site
  • Mackay Memorial Hospital
    Taipei, 10448, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05826704
Lead sponsor
Mackay Memorial Hospital
Collaborators
Bened Biomedical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Dec 30, 2022
Primary completion
Dec 31, 2023
Completion
Apr 30, 2024
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion